Markets:

Overview

News

Currencies

International

Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

19.39 +0.53 (+2.81%)

Delayed Quote Updated: 11:16 AM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Mid-Morning Market Update: Markets Rise; Delta Air Lines Profit Tops Estimates ↗

January 13, 2022

Following the market opening Thursday, the Dow traded up 0.37% to 36,423.44 while the NASDAQ rose 0.12% to 15,206.73. The S&P also rose, gaining, 0.21% to 4,736.11. The U.S....

Via Benzinga

FDA Places Clinical Hold On Denali's Alzheimer's Potential Program ↗

January 13, 2022

The FDA has issued a clinical hold on Denali Therapeutics Inc's (NASDAQ: DNLI) Investigational New Drug (IND) application for DNL919 (ATV:TREM2). TREM2 is...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 13, 2022

Gainers iSpecimen (NASDAQ:ISPC) shares rose 19.8% to $8.18 during Thursday's pre-market session. The market value of their outstanding shares is at $71.4 million. VYNE...

Via Benzinga

Jim Cramer Says This Stock Is 'Really Cheap' ↗

December 16, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Academy Sports and Outdoors (NYSE:

Via Benzinga

Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program ↗

October 07, 2021

Denali Therapeutics Inc (NASDAQ: DNLI) announced data from the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 healthy volunteers. DNL343 was generally...

Via Benzinga

Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression

November 23, 2021

Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market....

Via FinancialNewsMedia

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗

October 03, 2021

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...

Via Benzinga

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021 ↗

September 21, 2021

Upgrades According to Compass Point, the prior rating for TriplePoint Venture Growth BDC Corp (NYSE:

Via Benzinga

President And CEO Of Denali Therapeutics Sold $1.00 Million In Stock ↗

September 03, 2021

Ryan Watts, President and CEO at Denali Therapeutics (NASDAQ:DNLI), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing...

Via Benzinga

Topics Regulatory Compliance

Why Denali Therapeutics Stock Is Sinking Today ↗

July 26, 2021

The company reported interim results from a phase 1/2 study of its experimental Hunter syndrome drug.

Via The Motley Fool

74 Biggest Movers From Yesterday ↗

July 27, 2021

Gainers Bit Digital, Inc. (NASDAQ: BTBT) shares jumped 109.7% to close at $8.87 on Monday after the company announced it entered into a second strategic co-mining agreement with...

Via Benzinga

48 Stocks Moving In Monday's Mid-Day Session ↗

July 26, 2021

Gainers Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic co-mining agreement with Digihost Technology Inc. The...

Via Benzinga

Denali Therapeutics Stock Crashes; Why Investors Are Questioning Its Entire Pipeline ↗

July 26, 2021

Denali unveiled promising test results in Hunter syndrome, but DNLI stock tanked Monday on broader pipeline viability questions.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 26, 2021

Gainers Dynatronics (NASDAQ:DYNT) shares moved upwards by 40.31% to $1.81 during Monday's pre-market session. The company's market cap stands at $31.4 million....

Via Benzinga

Denali's Brain-Penetrant Enzyme Therapy Shows Durable Effect With CNS Impact In Hunter Syndrome ↗

July 26, 2021

Denali Therapeutics Inc (NASDAQ: DNLI) announced additional interim data from a Phase 1/2 study evaluating ETV:IDS (DNL310) for the central nervous system (CNS)...

Via Benzinga

Tuesday Talk: Action! ↗

June 15, 2021

U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up...

Via Talk Markets

Topics Stocks

Biotechs Ready To Roar ↗

June 13, 2021

The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021 ↗

May 18, 2021

Upgrades Janney Montgomery Scott upgraded the previous rating for Centerspace (NYSE:CSR) from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95,...

Via Benzinga

Biden's Budget May Boost These 3 Biotechs ↗

May 10, 2021

It signals a big push toward curing a neurological disease with a massive market.

Via The Motley Fool

Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End ↗

May 03, 2021

Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.